<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294761</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00005823-SPARE2011</org_study_id>
    <secondary_id>UMIN000005116</secondary_id>
    <nct_id>NCT01294761</nct_id>
  </id_info>
  <brief_title>Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir</brief_title>
  <acronym>SPARE</acronym>
  <official_title>Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Global Health and Medicine, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Global Health and Medicine, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this clinical trial in randomizing HIV infected patients under good HIV&#xD;
      control with tenofovir (TDF), emtricitabine (or lamivudine) plus lopinavir/ritonavir (LPV/r)&#xD;
      into switching the regimen to raltegravir (RAL) with darunavir/ritonavir (DRV/r) or&#xD;
      continuing the ongoing regimen to compare these two groups' estimated glomerular filtration&#xD;
      rate (eGFR) is to investigate whether anti-HIV treatment that does not contain TDF or other&#xD;
      reverse-transcriptase inhibitors (NTRI sparing regimen) can be protective of patients' renal&#xD;
      functions and has the same virological efficacy in comparison with a standard treatment with&#xD;
      TDF, or not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria are HIV infected outpatients or inpatients that are:&#xD;
&#xD;
      without history virological failure including protease inhibitors or raltegravir&#xD;
      (disregarding whether the patient had a history of drug resistance or drug holiday, or not)&#xD;
      taking LPV/r+TVD (or TDF+lamivudine) for longer than 15 weeks before the enrollment with HIV&#xD;
      viral load less than 50 copies/ml for 15 weeks, including those with blips (one time episode&#xD;
      of detectable level HIV viraemia which are proceeded and followed by undetectable viraemia).&#xD;
&#xD;
      20 years old or older Japanese willing to participate in the trial and able to agree to the&#xD;
      informed consent. Main outcome measures are to investigate if the estimated glomerular&#xD;
      filtration rate (eGFR) of the intervened group with RAL+DRV/r improves by 10% or more by&#xD;
      intention to treat (ITT) analysis at the time of 48 weeks after the start of the trial.&#xD;
&#xD;
      Other outcome measures are:&#xD;
&#xD;
      virological efficacy of the group on DRV/r+RAL (after 48 weeks and up to 96 weeks) comparison&#xD;
      of other renal function markers between the two arms: serum creatinine, urine beta-2&#xD;
      microglobulin, tubular resorption rate of phosphate, urine albumin,&#xD;
      N-acetyl-beta-glucosaminidase, serum cystatin C, urine protein and urine glucose (after 48&#xD;
      weeks and up to 96 weeks) comparison of lipid markers between the two arms: triglycerides,&#xD;
      HDL cholesterol, LDL cholesterol and total cholesterol (after 48 weeks and up to 96 weeks)&#xD;
      discontinuation rate of each arm, reason and timing of the discontinuation or the treatment&#xD;
      change up to 96 weeks adverse events of each arm, symptoms and rate up to 96 weeks blood&#xD;
      plasma concentration level of RAL and DRV of all consented intervened cases at National&#xD;
      Center for Global Health and Medicine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR improvement comparison of two arms by ITT analysis</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate whether the estimated glomerular filtration rate (eGFR) of the intervened group with RAL+DRV/r improves by 10% or more by intention to treat (ITT) analysis at the time of 48 weeks after the start of the study, or not.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological efficacy</measure>
    <time_frame>48 weeks up to 96 weeks</time_frame>
    <description>Virological efficacy of the group on DRV/r+RAL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function markers</measure>
    <time_frame>48 weeks up to 96 weeks</time_frame>
    <description>Serum creatinine, eGFR, uine beta-2 microglobulin, tubular resorption rate of phosphate, urine albumin, N-acetyl-beta-glucosaminidase, serum cystatin C, urine protein and urine glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>48 weeks up to 96 weeks</time_frame>
    <description>Triglycerides, HDL cholesterol, LDL cholesterol and total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>96 weeks</time_frame>
    <description>Adverse events of each arm, symptoms and rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood plasma concentration of RAL and DRV</measure>
    <time_frame>96 weeks</time_frame>
    <description>Blood plasma concentration level of raltegravir and darunavir among all consented and intervened cases at National Center for Global Health and Medicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate</measure>
    <time_frame>96 weeks</time_frame>
    <description>Discontinuation rate of each arm, reason and timing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir, Darunavir/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD&#xD;
to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir, Emtricitabine, Lopinavir/r</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir, Darunavir/r</intervention_name>
    <description>An arm to change the regimen to: raltegravir and darunavir/ritonavir&#xD;
Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID&#xD;
from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD</description>
    <arm_group_label>Raltegravir, Darunavir/r</arm_group_label>
    <other_name>NRTI sparing regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: HIV infected outpatients or inpatients that are&#xD;
&#xD;
          -  without history virological failure including protease inhibitors or raltegravir&#xD;
             (disregarding whether the patient had a history of drug resistance or drug holiday, or&#xD;
             not)&#xD;
&#xD;
          -  taking LPV/r+TVD (or TDF+lamivudine) for longer than 15 weeks before the enrollment&#xD;
&#xD;
          -  with HIV viral load less than 50 copies/ml for 15 weeks, including those with blips&#xD;
             (one time episode of detectable level HIV viraemia which are proceeded and followed by&#xD;
             undetectable viraemia)&#xD;
&#xD;
          -  20 years old or older&#xD;
&#xD;
          -  Japanese&#xD;
&#xD;
          -  willing to participate in the trial and able to agree to the informed consent&#xD;
&#xD;
        Exclusion Criteria: cases applicable to any of the following will be excluded from this&#xD;
        trial&#xD;
&#xD;
          -  HBs antigen positive within 15 weeks to the enrollment (cases confirmed as HBs&#xD;
             antibody positive can be enrolled without HBs antigen testing)&#xD;
&#xD;
          -  malabsorption or gastrointestinal symptoms that affect absorption of the drugs, or&#xD;
             dysphagia cases&#xD;
&#xD;
          -  clinical data within 15 weeks before the start of the trial and of the closest date to&#xD;
             the enrollment that are GPT 2.5 times the highest of the normal range (grade 2) or&#xD;
             eGFR less than 60ml/min (Cockcroft-Gault formula)&#xD;
&#xD;
          -  cases with opportunistic infections requiring treatment (primary and secondary&#xD;
             preventive prophylaxis can be administrated during the study)&#xD;
&#xD;
          -  cases during pregnancy or nursing period, or with a possibility for pregnancy&#xD;
&#xD;
          -  using drugs that are prohibited to combine for drug interaction with the drugs of this&#xD;
             trial&#xD;
&#xD;
          -  other cases that are decided by the patient's physician as not suitable for the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shinichi Oka, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Global Health and Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>1628655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. eCollection 2013.</citation>
    <PMID>23951362</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>AIDS</keyword>
  <keyword>Clinical Trials, Randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

